NEW YORK — Fortis Life Sciences, a provider of capital and other resources to life science tool companies, said on Tuesday that it has signed a deal to distribute AccuGenomics' SNAQ-SEQ internal standards technology for next-generation sequencing in the US and Europe.
Under the terms of the deal, Waltham, Massachusetts-based Fortis will be AccuGenomics' exclusive channel partner in the US and co-exclusive channel partner in Europe. Additional terms were not disclosed.
"Our focus is on improving the accuracy and sensitivity of challenging liquid biopsy applications like minimal residual disease (MRD) detection," Dan Dilks, senior VP of business development at AccuGenomics, said in a statement. "This agreement with Fortis will accelerate the adoption of our differentiated internal spike in standards for targeted NGS assays like MRD while providing researchers and clinicians better access to our SNAQ technology, leading to more accurate and actionable variant calls across multiple precision medicine applications."
In mid-2021, Wilmington, North Carolina-based AccuGenomics won a $750,000 grant from the US Air Force to use the SNAQ-SEQ standards to improve the sensitivity and accuracy of COVID-19 variant analysis.